SEC Form 4 · accession 0001237899-16-000086
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard S Schleifer
Officer — President & CEO · Director
Period of report
Dec 15, 2016
Accepted (ET)
Dec 19, 2016 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 15, 2016 | M | 250,000 | $20.32 | A | 292,806 | D | |
| Common Stock | Dec 15, 2016 | F | 13,365 | $380.09 | D | 279,441 | D | |
| Common Stock | Dec 15, 2016 | F | 122,032 | $380.09 | D | 157,409 | D | |
| Common Stock | holding | — | — | — | 5,702 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $20.32 | Dec 15, 2016 | M | 250,000 | D | — | Dec 18, 2016 | Common Stock | 250,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2 | $381.92 | Dec 16, 2016 | A | 146,815 | A | — | Dec 16, 2026 | Common Stock | 146,815 | 146,815 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The stock option award vests in four equal annual installments, commencing one year after the date of grant.